Information Journal Paper
APA:
Copy. (2017). Safety findings from FORWARD II: A Phase 1b study evaluating the folate receptor alpha (FRα )-targeting antibody-drug conjugate (ADC) mirvetuximab soravtansine (IMGN853) in combination with bevacizumab, carboplatin, pegylated liposomal doxorubicin (PLD), or pembrolizumab in patients (pts) with ovarian cancer. JOURNAL OF CLINICAL ONCOLOGY, 35(-), 0-0. SID. https://sid.ir/paper/749877/en
Vancouver:
Copy. Safety findings from FORWARD II: A Phase 1b study evaluating the folate receptor alpha (FRα )-targeting antibody-drug conjugate (ADC) mirvetuximab soravtansine (IMGN853) in combination with bevacizumab, carboplatin, pegylated liposomal doxorubicin (PLD), or pembrolizumab in patients (pts) with ovarian cancer. JOURNAL OF CLINICAL ONCOLOGY[Internet]. 2017;35(-):0-0. Available from: https://sid.ir/paper/749877/en
IEEE:
Copy, “Safety findings from FORWARD II: A Phase 1b study evaluating the folate receptor alpha (FRα )-targeting antibody-drug conjugate (ADC) mirvetuximab soravtansine (IMGN853) in combination with bevacizumab, carboplatin, pegylated liposomal doxorubicin (PLD), or pembrolizumab in patients (pts) with ovarian cancer,” JOURNAL OF CLINICAL ONCOLOGY, vol. 35, no. -, pp. 0–0, 2017, [Online]. Available: https://sid.ir/paper/749877/en